We have located links that may give you full text access.
Favorable Response of 225Ac-PSMA in the Treatment of Castration-Resistant Prostate Cancer With High Bone Metastasis Burden.
Clinical Nuclear Medicine 2024 April 5
225Ac-PSMA treatment demonstrated low hematologic toxicity for prostate cancer with diffuse red marrow infiltration. A 70-year-old man with diffuse bone metastases of castration-resistant prostate cancer received 225Ac-PSMA radiation therapy. After 1 treatment cycle, the patient's skeletal lesions demonstrated a significant response and a significant decrease in PSA. 225Ac-PSMA may be a promising therapeutic option for metastatic castration-resistant prostate cancer patients with high bone metastatic burden.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app